Inflamatory Bowel Disease
Conditions
Keywords
inflamatory bowel, inflammation, Interleukins, IL-10, supplements, curcumin
Brief summary
This pilot, genotype-stratified clinical trial aims to evaluate the safety and preliminary efficacy of liposomal curcumin in patients with inflammatory bowel disease (IBD) who are homozygous for a specific unfavorable IL-10 gene variant (e.g., rs1800896). The study will compare clinical and inflammatory markers in two cohorts: (1) homozygous carriers of the IL-10 variant and (2) non- carriers. The hypothesis is that curcumin supplementation will lead to more pronounced improvement in clinical activity scores and inflammatory biomarkers among homozygous carriers due to their inherently reduced anti-inflammatory capacity.
Detailed description
Inflammatory bowel diseases (including Crohn's disease and ulcerative colitis) are characterized by chronic intestinal inflammation driven by a complex interplay of genetic, immune, and environmental factors. IL-10 plays a crucial role in anti-inflammatory pathways; certain genetic variants can reduce IL-10 production and predispose patients to more severe disease phenotypes. Curcumin, a polyphenol derived from turmeric, has shown anti-inflammatory effects via multiple molecular targets, including NF-κB. However, curcumin's bioavailability is limited; liposomal formulations may enhance its absorption and therapeutic impact. This pilot trial examines whether liposomal curcumin provides a more significant clinical benefit specifically in patients with the homozygous IL-10 variant, as this subgroup may be particularly responsive to additional anti- inflammatory support.
Interventions
DIETARY_SUPPLEMENTliposomal curcumin
Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.
DIETARY_SUPPLEMENTLiposomal Curcumin
Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.
Sponsors
S.LAB (SOLOWAYS)
Study design
Allocation
NA
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
\- Adults aged 18-70 years with a confirmed diagnosis of ulcerative colitis or Crohn's disease. Stable background IBD treatment regimen (5-ASA, immunomodulators, or low-dose corticosteroids) for at least 4 weeks prior to enrollment. * Willingness to undergo genotyping for the IL-10 variant and to comply with the study protocol. * For the IL-10 Homozygous Variant Cohort: confirmed homozygous unfavorable variant (e.g., rs1800896) prior to enrollment. 5. For the Non-Variant Cohort: confirmed absence of the unfavorable allele (wild-type).
Exclusion criteria
* Use of high-dose corticosteroids or biologics (e.g., TNF inhibitors) initiated within 4 weeks prior to enrollment. * Known allergy or hypersensitivity to curcumin or related compounds. Severe concomitant illness (significant liver or renal dysfunction, uncontrolled diabetes, etc.) that could interfere with interpretation of results or patient safety. * Pregnancy or breastfeeding. * Inability to provide informed consent or comply with study procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Clinical Disease Activity Index | 12 weeks | Change in the Mayo Clinic Score from baseline to 12 weeks will be assessed for patients with ulcerative colitis. The Mayo Clinic Score is a composite index with four components (stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment), each rated 0 to 3, resulting in a total score ranging from 0 to 12. Higher scores indicate worse disease activity. |
| For Crohn's disease: Crohn's Disease Activity Index | 12 Weeks | Change in the Crohn's Disease Activity Index (CDAI) from baseline to 12 weeks will be assessed for patients with Crohn's disease. The CDAI is calculated from multiple clinical variables and typically ranges from 0 to approximately 600, with higher scores indicating more active disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Additional Cytokines TNF-α | 12 weeks | — |
| Change in Additional Cytokines IL-1β | 12 weeks | — |
| Change in High-sensitivity C-Reactive Protein (hs-CRP) Concentration | 12 weeks | Change in serum high-sensitivity C-reactive protein (hs-CRP) concentration (measured in mg/L) from baseline to 12 weeks. The outcome will be reported as the mean change in hs-CRP concentration. |
| Change in Patient-Reported Quality of Life as Measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) | 12 weeks | Description: Patient-reported quality of life will be assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ). The IBDQ total score ranges from 32 to 224, where higher scores indicate a better quality of life. The outcome will be reported as the mean change in IBDQ total score from baseline to 12 weeks. |
| Adverse Events | 12 weeks | — |
| Change in Fecal Calprotectin Concentration | 12 weeks | Change in fecal calprotectin concentration (measured in µg/g) from baseline to 12 weeks will be assessed. The outcome will be reported as the mean change in fecal calprotectin concentration. |
Countries
Russia
Outcome results
None listed